World Pharma News

AUGUST 26, 2024

A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic. New Griffith University research, published in Nature Communications, has been testing the efficacy of delivering a COVID-19 vaccine via the nasal passages.

Vaccines 100

Vaccines Communication 100

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Communication 81

Communication Vaccines HIPAA Documentation 81

Express Pharma

AUGUST 27, 2024

Indian Immunologicals Limited (IIL) has announced the development of a live-attenuated, needle-free intranasal booster vaccine against SARS-CoV-2. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over.

Vaccines 104

Vaccines Immunity Immunization Communication 104

pharmaphorum

MAY 19, 2022

The likelihood of long COVID symptoms was found to decrease after COVID-19 vaccination, and evidence pointed to an even greater improvement after a second dose. However, the authors say more data is needed before vaccination can be considered a treatment for the condition.

Vaccines 124

Vaccines Immunity Immunization Communication 124

Pharmaceutical Technology

JUNE 20, 2025

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi. Give your business an edge with our leading industry insights.

Vaccines 52

Vaccines Pharmaceutical Manufacturing Communication Hospitals 52

European Pharmaceutical Review

MARCH 6, 2023

The first clinical trial of any subunit tuberculosis (TB) vaccine in a temperature-stable form has found that ID93+GLA-SE, a freeze-dried vaccine, was safe. The recombinant subunit vaccine is made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant.

Immunity 103

Immunity Immunization Vaccines Communication 103

Pharmaceutical Technology

DECEMBER 11, 2022

The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.

Vaccines 115

Vaccines Communication 115

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.

Vaccines 115

Vaccines Communication 115

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.

Vaccines 98

Vaccines Communication Immunity Immunization 98

pharmaphorum

DECEMBER 17, 2020

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. When we talk about vaccines as health professionals, people who are vehemently anti-vaccine can take it out of context for their agenda.

Vaccines 97

Vaccines Communication Immunity Immunization 97

Pharmacy Times

MARCH 21, 2025

The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.

Vaccines 72

Vaccines Communication 72

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunity Immunization Communication 98

Pharmaceutical Technology

JUNE 25, 2025

GlobalData Healthcare June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Changes to ACIP could result in regulatory uncertainty for vaccine developers and manufacturers. Malone, an early mRNA pioneer, has made unfounded claims regarding the dangers of mRNA vaccines, which have sparked significant public backlash.

Vaccines 52

Vaccines Hospitals Packaging Communication 52

Pharmafile

JANUARY 23, 2023

Indian biotech company Bharat Biotech plans to launch its new intranasal COVID-19 vaccine iNCOVACC on the 26 January 2023 ‒ the vaccine is the first of its kind to be developed in India. read more

Vaccines 98

Vaccines Communication 98

Express Pharma

AUGUST 23, 2023

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Vaccines 98

Vaccines Documentation Immunity Immunization 98

Pharmafile

MARCH 2, 2023

Yesterday, GSK shared that an advisory committee from the FDA voted in support of its respiratory syncytial virus (RSV) vaccine candidate for older adults. This support is ahead of an official FDA approval for the company’s vaccine. GSK has shared that a final decision is expected to be made by the FDA ahead of the 3 May. read more

Vaccines 98

Vaccines Communication 98

Express Pharma

JUNE 20, 2023

The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Finally, public engagement in research has to be sought through informal group sessions communicating the purpose of the human research in plain language.

Immunity 105

Immunity Immunization Vaccines Hospitals 105

Pharmaceutical Technology

MAY 22, 2023

The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vaccines 116

Vaccines Communication 116

Pharmacy Times

NOVEMBER 16, 2022

Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients. Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

JANUARY 31, 2023

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Moderna ’s investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) in adult patients. The investigational mRNA-1345 vaccine uses the same lipid nanoparticles (LNPs) that are also used in the Moderna Covid-19 vaccines.

Vaccines 72

Vaccines Communication 72

Pharmacy Times

AUGUST 10, 2023

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

Vaccines 49

Vaccines Communication 49

Pharmafile

JANUARY 13, 2023

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.

Vaccines 78

Vaccines Communication 78

Pharmafile

DECEMBER 23, 2022

BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which aims to develop a multi-antigen malaria vaccine.

Vaccines 80

Vaccines Communication 80

Pharmacy Times

NOVEMBER 10, 2022

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, leads a discussion on the challenges subvariants of SARS-CoV-2 present in terms of vaccination and approaching optimal communication to the public surrounding vaccination.

Vaccines 49

Vaccines Communication 49

Pharmaceutical Technology

APRIL 25, 2023

As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.

Vaccines 69

Vaccines Communication Pharmaceutical Companies Pharmaceutical Companies 69

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccines 59

Vaccines Communication 59

Pharmacy Times

MAY 12, 2025

A panelist discusses how physicians can collaborate with community pharmacists to enhance respiratory syncytial virus (RSV) vaccine uptake by leveraging pharmacists' expertise in patient education, addressing vaccine hesitancy through empathetic communication, and emphasizing the safety, benefits, and risks of RSV vaccination.

Vaccines 26

Vaccines Communication 26

Pharmafile

APRIL 24, 2023

Sanofi has introduced a hepatitis A vaccine for children aged between one to 15 years old in the UK. The vaccine, inactive AVAXIM Junior, will consist of two doses injected intramuscularly six to 36 months apart. It is the most common form of viral hepatitis and the third most common vaccine-preventable infection among travellers.

Vaccines 59

Vaccines Communication 59

Pharmaceutical Technology

MAY 4, 2023

After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).

Vaccines 64

Vaccines Communication Immunity Immunization 64

Pharmacy Times

MAY 21, 2025

RSV vaccination for older adults requires understanding risk factors, using empathetic communication strategies and proactively identifying eligible patients through careful review of medical histories and care transitions.

Vaccines 26

Vaccines Communication 26

Pharmafile

MARCH 15, 2023

Yesterday, the FDA announced that it has amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech bivalent COVID-19 Vaccine. read more

Vaccines 59

Vaccines Communication 59

Pharmacy Times

JULY 22, 2022

Pharmacists discuss the impacts of inaccuracy on vaccine hesitancy and offer communication strategies for conversations with patients.

Vaccines 37

Vaccines Communication 37

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccines 52

Vaccines Immunity Immunization Communication 52

Pharmaceutical Technology

DECEMBER 13, 2022

To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. In an ever-changing environment, more robust and scalable communications solutions are required.

Vaccines 52

Vaccines Communication Documentation 52

Pharmafile

APRIL 28, 2023

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) for the prevention of invasive pneumococcal disease (IPD) in infants and children from six weeks to 17 years of age. read more

Vaccines 59

Vaccines Communication 59

Pharmafile

DECEMBER 9, 2022

Pfizer has announced that the FDA has accepted its application for a respiratory syncytial virus (RSV) vaccine for older adults, with the FDA expected to come to a decision by Spring 2023. The FDA will review the application under the priority review programme, meaning the approval timeline should be reduced by four months. read more.

Vaccines 59

Vaccines Communication 59